Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachary Spencer Dunn

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cells|December 24, 2021
Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer ImmunotherapiesYan-Ruide Li, Zachary Spencer Dunn, Yang Zhou, et al.
Cell Stem Cell|March 22, 2023
Advancing cell-based cancer immunotherapy through stem cell engineeringYan-Ruide Li, Zachary Spencer Dunn, Yanqi Yu, et al.
Cancers|June 24, 2022
Human γδ T Cell Subsets and Their Clinical Applications for Cancer ImmunotherapyDerek Lee, Carl J Rosenthal, Natalie E Penn, et al.
Cancers|May 14, 2022
Engineering Induced Pluripotent Stem Cells for Cancer ImmunotherapyYang Zhou, Miao Li, Kuangyi Zhou, et al.
Scientific Reports|June 11, 2021
Efficient facemask decontamination via forced ozone convectionJoseph Schwan, Troy R Alva, Giorgio Nava, et al.
Iscience|August 29, 2022
Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancersYan-Ruide Li, Samuel Zeng, Zachary Spencer Dunn, et al.
Cancers|June 10, 2022
Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor ReactivityYan-Ruide Li, James Brown, Yanqi Yu, et al.
Stem Cell Research & Therapy|March 22, 2022
Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic interventionYan-Ruide Li, Zachary Spencer Dunn, Gustavo Garcia, et al.
Cancers|April 12, 2022
Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor MicroenvironmentZachary Spencer Dunn, Yan-Ruide Li, Yanqi Yu, et al.
Nature Communications|November 8, 2023
Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineeringDerek Lee, Zachary Spencer Dunn, Wenbin Guo, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cells|December 24, 2021
Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer ImmunotherapiesYan-Ruide Li, Zachary Spencer Dunn, Yang Zhou, et al.
Cell Stem Cell|March 22, 2023
Advancing cell-based cancer immunotherapy through stem cell engineeringYan-Ruide Li, Zachary Spencer Dunn, Yanqi Yu, et al.
Cancers|June 24, 2022
Human γδ T Cell Subsets and Their Clinical Applications for Cancer ImmunotherapyDerek Lee, Carl J Rosenthal, Natalie E Penn, et al.
Cancers|May 14, 2022
Engineering Induced Pluripotent Stem Cells for Cancer ImmunotherapyYang Zhou, Miao Li, Kuangyi Zhou, et al.
Scientific Reports|June 11, 2021
Efficient facemask decontamination via forced ozone convectionJoseph Schwan, Troy R Alva, Giorgio Nava, et al.
Iscience|August 29, 2022
Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancersYan-Ruide Li, Samuel Zeng, Zachary Spencer Dunn, et al.
Cancers|June 10, 2022
Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor ReactivityYan-Ruide Li, James Brown, Yanqi Yu, et al.
Stem Cell Research & Therapy|March 22, 2022
Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic interventionYan-Ruide Li, Zachary Spencer Dunn, Gustavo Garcia, et al.
Cancers|April 12, 2022
Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor MicroenvironmentZachary Spencer Dunn, Yan-Ruide Li, Yanqi Yu, et al.
Nature Communications|November 8, 2023
Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineeringDerek Lee, Zachary Spencer Dunn, Wenbin Guo, et al.
Pageof 2